Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults
The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.
BlackDoctor.org20h
Beyond the Twitch: How TD Affects Us Far More Than We Realize
Let’s discuss how Tardive Dyskinesia (TD) affects your life and what you can do to overcome these difficulties.
Neurocrine begins Phase 1 clinical study of NBI-1140675
Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...
The Pharma Letter6d
Phase IV Ingrezza data move focus from sales outlook
Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...
Neurocrine reports patient-reported outcome data from KINECT-PRO study
Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...